Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Chemical Communications (Cambridge, England)|October 21, 2011
One-pot reduction of graphene oxide at subzero temperaturesPeng Cui, Junghyun Lee, Eunhee Hwang, et al.
Scientific Reports|September 15, 2016
Mesoporous Non-stacked Graphene-receptor Sensor for Detecting Nerve AgentsHee Min Hwang, Eunhee Hwang, Doyoung Kim, et al.
The Primary Care Companion for CNS Disorders|December 23, 2015
Efficacy of Desvenlafaxine 50 mg/d Versus Placebo in the Long-Term Treatment of Major Depressive Disorder: A Randomized, Double-Blind TrialPatrice Boyer, Cécile Vialet, Eunhee Hwang, et al.
Angewandte Chemie (International Ed. in English)|August 10, 2017
Functional Molecular Junctions Derived from Double Self-Assembled MonolayersSohyeon Seo, Eunhee Hwang, Yunhee Cho, et al.
Chemical Communications (Cambridge, England)|March 24, 2012
Nonvolatile resistive memory of ferrocene covalently bonded to reduced graphene oxideChanghua Jin, Junghyun Lee, Eunkyo Lee, et al.
BMC Psychiatry|March 23, 2013
A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorderMichael R Liebowitz, Karen A Tourian, Eunhee Hwang, et al.
Chemical Communications (Cambridge, England)|June 28, 2012
Binol salt as a completely removable graphene surfactantSurajit Some, Youngmin Kim, EunHee Hwang, et al.
Menopause (New York, N.Y.)|September 27, 2012
Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trialJoAnn V Pinkerton, Ginger Constantine, Eunhee Hwang, et al.
Journal of Psychiatric Practice|January 22, 2013
Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatientsNakao Iwata, Karen A Tourian, Eunhee Hwang, et al.
The Journal of Clinical Psychiatry|March 12, 2013
Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trialJoshua Z Rosenthal, Patrice Boyer, Cécile Vialet, et al.
Pageof 4